Investigation Report on Chinese Latanoprost Market, 2018-2022


Description
According to WHO's data in 2005, glaucoma is the second leading cause of blindness after cataracts and the most common irreversible cause of blindness in the world. There are 70 million glaucoma patients worldwide, and it is estimated that the number will reach 80 million in 2020. Blindness caused by glaucoma accounts for 50% of global blindness. China has the largest number (over 24 million) of glaucoma patients in the world, and this number is growing at a rate of more than 1.5 million per year. 
Latanoprost is the first FDA approved prostaglandin for intraocular pressure reduction. In 1999, China began importing Latanoprost as a first-line drug in the clinical treatment of glaucoma. In 2004, Latanoprost eye drops developed by Lunan Better were approved for sale, followed by the products of other domestic manufacturers. And there is a continuous rise in the market share of domestic manufacturers. In 2017, Pfizer had the largest market share by sales value, about 39%, a figure that has been declining in recent years. 
According to CRI, Latanoprost has been growing since it entered China, with its sales value exceeding CNY 40 million in 2017. With an ageing population, the incidence of glaucoma is increasing year by year in China. In clinical practice, glaucoma cannot be well treated through operations as cataracts. Therefore, there is a promising market of conservative medications and post-operative medications, and thus a high demand for Latanoprost in China. 

Topics Covered:
- Development environment of Latanoprost in China
- Sales of Latanoprost in China
- Major Latanoprost manufacturers in China
- Retail prices of Latanoprost in China
- Prospects of Chinese Latanoprost market
Table of Contents
1 Basic Concepts of Latanoprost
1.1 Indications for Latanoprost
1.2 Development History of Latanoprost in China
1.3 Governmental Approval of Latanoprost in China

2 Investigation on Sales of Latanoprost in China, 2013-2017
2.1 Sales Value of Latanoprost in China
2.1.1 Overall Sales Value
2.1.2 Sales Value in Parts of China
2.2 Sales Value of Latanoprost in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Parts of China
2.3 Sales of Latanoprost in China by Dosage Form

3 Major Latanoprost Manufacturers in China
3.1 Market Competition of Latanoprost in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer 
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer's Latanoprost in China
3.3 Pharmacia 
3.3.1 Enterprise Profile
3.3.2 Sales of Pharmacia's Latanoprost in China
3.4 Lunan Better Pharmaceutical Co., Ltd. 
3.5 China Resources Zizhu Pharmaceutical Co., Ltd. 
3.6 Taejoon Pharm
3.7 Chengdu Hengrui Pharmaceutical Co., Ltd.  

4 Analysis on Prices of Latanoprost in China, 2017-2018
4.1 Prices of Latanoprost in China
4.1.1 National Average Price
4.1.2 Average Price by Region
4.2 Prices of Major Manufacturers' Latanoprost in China
4.2.1 Pfizer (Xalatan)
4.2.2 Pharmacia (Xalatan)
4.2.3 Lunan Better Pharmaceutical Co., Ltd. (Telijie)
4.2.4 China Resources Zizhu Pharmaceutical Co., Ltd. (Jiankang)
4.2.5 Taejoon Pharm (Ruidaxi)
4.2.6 Chengdu Hengrui Pharmaceutical Co., Ltd. (Shengao)

5 Prospects of Chinese Latanoprost Market, 2018-2022
5.1 Factors Influencing Latanoprost Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Competition Pattern

Selected Charts
Chart Governmental Approval of Latanoprost in China
Chart Sales Value of Latanoprost in China, 2013-2017
Chart Sales Value of Latanoprost in Parts of China, 2013-2017
Chart Sales Volume of Latanoprost in China, 2013-2017
Chart Sales Volume of Latanoprost in Parts of China, 2013-2017
Chart Market Share and Sales Value of Pfizer's Latanoprost in China, 2013-2017
Chart Market Share and Sales Value of Pharmacia's Latanoprost in China, 2013-2017
Chart Market Share and Sales Value of Lunan Better Pharmaceutical Co., Ltd.'s Latanoprost in China, 2013-2017
Chart Prices of Pfizer's Latanoprost in Several Chinese Cities, 2017-2018
Chart Prices of Pharmacia's Latanoprost in Several Chinese Cities, 2017-2018
Chart Prices of Lunan Better Pharmaceutical Co., Ltd.'s Latanoprost in Several Chinese Cities, 2017-2018
Chart Forecast on Sales Value of Latanoprost in China, 2018-2012


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Finasteride Market, 2019-2023

Description The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases w...

Investigation Report on China's Prothrombin Complex Concentrate (PCC) Market, 2019-2023

Description Hemophilia is an X-linked recessive hemorrhagic disease. It is classified into hemophilia A, a deficiency in clotting factor VIII and hemophilia B, a deficiency in clotting factor IX. Both hemophilia A and hemophilia B are caused by gene ...

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023

Description In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver...

Investigation Report on China's Pegaspargase Market, 2019-2023

Description According to the data released by China?s National Health Commission in Oct. 2018, the incidence of childhood leukemia in Chinese children under 15 is about 4/100,000 to 5/100,000, and the number of childhood leukemia patients under 18 ol...

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

New Chemicals and Advanced Materials Reports

Publisher: China Research and Intelligence